Fonar posts larger loss in fiscal 1999

Article

Increased revenue from its healthcare services business wasn’t enough to bring profitability to MRI developer Fonar. During its 1999 fiscal year (end-June), the Melville, NY-based open MRI developer posted revenues of $36.9 million, a 34% increase

Increased revenue from its healthcare services business wasn’t enough to bring profitability to MRI developer Fonar. During its 1999 fiscal year (end-June), the Melville, NY-based open MRI developer posted revenues of $36.9 million, a 34% increase over last year’s $27.6 million, but also sustained a net loss of $14.2 million, more than double 1998’s $5.7 million.

Fonar attributed its loss to low scanner sales and expenses related to the R&D of four new MRI products, but emphasized the growth of its physician practice management subsidiary, Health Management Corp. of America (HMCA). Its revenues climbed from $21.1 million in 1998 to $31.3 million in 1999, a 48% increase. In September, Fonar announced it will sell its MRI scanners to HMCA in an effort to upgrade select facilities and improve the subsidiary’s operating profits and productivity (SCAN 9/29/99).

In other Fonar news, the company moved to strengthen its stock repurchase program, announcing that it will purchase its shares on an ongoing basis and will consider a stock purchase plan for its employees. The company believes that it is on the cusp of dynamic growth as it continues R&D on works-in-progress scanners such as Open Sky MRI, Fonar OR-360, and Stand-Up MRI, for which it hopes to obtain clearance from the FDA next year. In an effort to facilitate this growth, Fonar also announced Oct. 27 that it has sold the stock of its subsidiary, Medical SNI of Haifa, Israel, which designs and develops medical imaging and archiving products. The sale will free Fonar from liabilities of roughly $1.2 million, and will give Fonar a pre-tax gain of $1 million.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.